SNCA and Dyskinesia: In both studies, no obvious differences emerged according to mutation type, but good levodopa responsiveness was more frequently observed in SNCA duplication and triplication carriers compared to p.G51D mutation carriers, despite a higher rate of motor and non-motor adverse events (dystonia, dyskinesias, hallucinations, psychosis) [48,272].